XSpray’s new share issue oversubscribed

On November 8, 2016 XSpray Microparticles AB, a clinical stage product development company that creates improved and generic versions of existing cancer products, reported the successful completion of a new share issue of SEK 41 million (Press release, XSpray, NOV 8, 2016, View Source [SID1234516858]).
"I’m pleased with the strong interest from both existing and more than 70 new investors. The proceeds from this share issue will allow us to continue to progress our lead product candidate, XS-004, further in clinical development with the goal to achieve next relevant clinical milestone during the first half of 2017 as well as expanding our internal product pipeline with new high value product candidates, "says Per Andersson, CEO of XSpray.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!